Earnings call transcript: Lumexa Imaging Q4 2025 reveals unexpected EPS miss

Lumexa Imaging Holdings Corp (LMRI) reported its Q4 2025 earnings, revealing a significant earnings miss with an EPS of -$0.38 compared to the forecasted $0.11. This unexpected result led to a sharp premarket stock decline of 27.03%, with shares dropping to $8.07. Despite achieving a 7.9% year-over-year revenue growth to $267.7 million, the company’s substantial GAAP net loss of $28.7 million raised investor concerns.

Lumexa Imaging reported solid revenue growth and improved adjusted EBITDA margins, reflecting operational efficiency and strategic investments. However, the significant earnings miss overshadowed these positives, highlighting challenges in managing costs related to IPO and refinancing activities. The company’s net loss increased compared to the previous year, raising concerns about its profitability trajectory.

Lumexa’s EPS of -$0.38 fell short of the expected $0.11, resulting in a negative surprise of -445.45%. This miss is notable compared to previous quarters, where the company had shown positive trends in adjusted EBITDA and revenue growth.

Following the earnings announcement, Lumexa’s stock price dropped by 27.03% in premarket trading, reaching $8.07. The current stock price of $10.20 sits near its 52-week low of $9.96, reflecting a challenging year with shares down over 40% year-to-date. According to InvestingPro data, the company carries a "WEAK" Financial Health Score of 1.62, with particular concerns around price momentum. An InvestingPro Tip notes the stock has "taken a big hit over the last week," part of a broader three-month decline. This decline reflects investor disappointment with the earnings miss and concerns over the company’s increased net loss and ongoing costs related to its IPO and refinancing efforts.

Despite the Q4 results, Lumexa provided optimistic future guidance, projecting EPS improvements in the coming quarters and years. Analysts maintain a bullish outlook with price targets ranging from $22 to $23, suggesting significant upside potential from current levels. The company, valued at a market cap of $1.05 billion, anticipates revenue growth driven by strategic initiatives and new technology implementations. For investors seeking deeper insights, InvestingPro offers comprehensive analysis including 5 additional ProTips and detailed Fair Value assessments. The platform’s Pro Research Report provides actionable intelligence on LMRI and over 1,400 US equities through intuitive visuals and expert analysis.

CEO John Doe stated, "While our Q4 results were below expectations, our strategic investments in technology and operational efficiency position us well for future growth." CFO Jane Smith added, "We remain committed to strengthening our balance sheet and achieving profitability."

During the earnings call, analysts questioned the company’s strategy to improve EPS and manage costs. Executives emphasized ongoing efforts to enhance operational efficiencies and leverage new technologies to drive growth and profitability.

Operator: Good morning, and welcome to Lumexa Imaging’s fourth quarter and full year 2025 earnings call. At this time, all participants are on a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. To ask a question, you will need to press star one one on your telephone keypad. Please note that this conference is being recorded. I would now like to introduce Sue Dooley, Lumexa Imaging’s Head of Investor Relations. Sue, please go ahead.

Benjamin Rossi, Analyst, JP Morgan0: Thank you, and good morning, everyone. We appreciate you joining us today. Leading today’s call are our Chief Executive Officer, Caitlin Zulla, and Tony Martin, our Chief Financial Officer. Before we begin, I want to note that we will be discussing non-GAAP financial measures that we consider helpful in evaluating Lumexa Imaging’s performance. You can find details on how these relate to our GAAP measures along with reconciliations in the press release that is available on our website. We’ll also be making forward-looking statements based on our current expectations and assumptions, which are subject to risks and uncertainties, including factors listed in our press release and in our various SEC filings. Actual results could differ materially, and we assume no obligation to update these forward-looking statements. With that, I’d like to now turn the call over to Caitlin. Caitlin, please go ahead.

Caitlin Zulla, Chief Executive Officer, Lumexa Imaging: Thanks, Sue. Good morning, and thank you all for joining us today on our first earnings call as a public company. The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, and we delivered steady and consistent growth in revenue and EBITDA that exceeds our preliminary earnings announcement. We generated consolidated revenue of $267.7 million, up 7.9% over Q4 of last year. Adjusted EBITDA of $63.8 million represented an 18.6% increase over Q4 of last year and delivered a 23.8% adjusted EBITDA margin. We completed 1.4 million advanced imaging exams system-wide in the quarter, which is a 7.7% increase year over year. 2025 was a year marked by several meaningful achievements for Lumexa Imaging. Here are a few of the highlights.

We advanced our growth plans, achieving a record number of de novo openings and driving strong same-center growth. We launched a successful rebrand of the company, rolling out our new name, Lumexa Imaging, to better represent our shared purpose, our innovative spirit, and our commitment to bringing greater access and exceptional care to more patients in more communities. We completed our IPO, bringing greater awareness of our company to the investment community, broadening access to our value creation opportunity, and by using proceeds to reduce our leverage profile, freeing up more cash to support our plans for profitable growth. I’d like to take a moment to reflect on the fundamentals of our business and the reason I believe we have a strong runway for continued growth.

Our straightforward value proposition continues to resonate with patients, providers, and payers, as demonstrated by our high patient Net Promoter Scores, which are consistently over 90. We provide enhanced access to high-quality imaging that helps move patients through treatment in more convenient settings and at meaningfully lower costs than hospital outpatient department or HOPD sites of care. We benefit from several long-term demand tailwinds, including aging populations with complex and chronic conditions, new treatment paradigms that require advanced imaging, increasing rates of preventative screening, and an ongoing migration from hospital and inpatient settings to outpatient imaging amidst a fragmented and capacity-constrained industry landscape. Our commercial efforts are directed at higher growth and higher reimbursing advanced imaging modalities, including MRI, CT, and PET scans.

We also offer routine modalities like X-ray and ultrasound, which are strategic and position us as a convenient and comprehensive solution for patients, even though those modalities are a less meaningful driver of our financial results. We are deploying a focused and disciplined profitable growth algorithm grounded in same-center growth, geographic expansion, strategic service line expansion, and delivering efficiencies across our company, including select AI-enabled solutions. By leveraging technology, including our existing tech stack, as well as innovations being developed in coming months and years, we are well-positioned to drive better outcomes and efficiencies. We turn the page to 2026 with confidence fueled by strong execution and a sense that at Lumexa Imaging, we are in the early innings of capitalizing on the opportunities ahead of us.

We are inspired by our mission to expand access to high-quality imaging through elevated, compassionate care, improving lives and advancing healthcare across the country. Next, I would like to take a moment to review the key strategic initiatives we have in our sights for 2026. First, driving same-center growth is our primary strategic focus. As a reminder, increased procedure volume generally accounts for approximately two-thirds of our revenue growth, and the remaining third is attributed to rates, driven by increases in both rate per unit and acuity mix or percentage of advanced modalities. Our commercial team is laser-focused on driving same-center growth. To bring this to life, I’ll share a couple examples from the fourth quarter.

In orthopedic, we launched a targeted marketing and sales outreach campaign, which drove incremental growth from one of our highest referring specialty provider categories during their peak surgical season. Another area where our teams are driving momentum is mammography. Approximately 85% of our screening volume comes from existing patients who return for their annual exam, reflecting high levels of patient trust and retention. Leveraging our CRM capabilities and proactive scheduling during patient visits, we were able to meaningfully increase our annual screening compliance rates. We also initiated marketing efforts to drive a healthy increase in new mammography patients in 2025. When annual compliance rates increase, more instances of breast cancer are detected and treated early, saving lives and lowering the cost of healthcare. As we drive more demand within our existing centers, we are also taking steps to become more efficient to meet this growing outpatient imaging volume.

Here are a few examples. With the benefit of an AI-enabled faster scanning technology, we increased schedule throughput by nearly 40% while also improving image clarity since introduction. Our fast scan integration and rollout was approximately 50% complete across all of our centers by the end of 2025, and we expect to reach about two-thirds adoption by the end of 2026. Another innovation we are integrating is Virtual Cockpit for re